In order to lower the high glycolytic rates in tumor organoids, we first administered 2-deoxyglucose (2-DG), a glucose analogue that cannot be metabolized and accumulates in the cell leading to reduced glycolysis by the inhibition of hexokinase-2 (HK2; Fig. 6a; reviewed in ref. 68). This evidence concerns the gene HK2 and neoplasm.